Skip to main content Back to Top


Meropenem Injection

Reason for the Shortage

    • BBraun had meropenem on shortage due to increased demand.
    • Fresenius Kabi states the reason for the shortage was increased demand.
    • Hospira has meropenem available.
    • Sandoz discontinued meropenem injection in January 2015.
    • AstraZeneca had Merrem on shortage due to increase demand.

Available Products

    • Merrem injection, AstraZeneca, 1 gram, vial, 10 count, NDC 00310-0321-30
    • Merrem injection, AstraZeneca, 500 mg, vial, 10 count, NDC 00310-0325-20
    • Meropenem injection, BBraun, 1 gm/50 mL, premixed bag, 24 count, NDC 00264-3185-11
    • Meropenem injection, BBraun, 500 mg/50 mL, premixed bag, 24 count, NDC 00264-3183-11
    • Meropenem injection, Fresenius Kabi, 1 gram, vial, 10 count, NDC 63323-0508-30
    • Meropenem injection, Fresenius Kabi, 500 mg, vial, 10 count, NDC 63323-0507-20
    • Meropenem injection, Pfizer, 1 gram, vial, 25 count, NDC 00409-3506-01
    • Meropenem injection, Pfizer, 500 mg, vial, 25 count, NDC 00409-3505-01

Estimated Resupply Dates

    • All marketed presentations are available.


Updated May 17, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. Created August 6, 2015 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.



Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.